Checkpoint inhibitor monotherapy has demonstrated the most significant activity in tumor types with high PD-L1 expression and/or high microsatellite instability or mismatch repair deficiency, though this is limited to no more than one-third of cancer patients authorized for checkpoint inhibitor treatment (163). The gene discussed is CD274; the disease is neoplasm.